Newsfeeds - Spark Newswire

1 minute read

Takeda’s Maribavir Reduces Hospitalization Rates, Hospital Stay In Post-Transplant Infection Patients

Today, 8:40 PM

Takeda Pharmaceutical Co Ltd (NYSE:TAK) shared new analyses of Livtencity (maribavir), including additional analyses from Phase 3 SOLSTICE trial data, which…

TAK

1 minute read

News

Takeda Pharmaceutical Company Reports In 13D Filing A New 13.2% Stake In Calithera Biosciences

By Benzinga Newsdesk

Today, 8:40 PM

-SEC Filing

CALA

1 minute read

Japan’s Health Ministry Panel OKs Approval Of Novavax’s COVID-19 Vaccine: Report

By Vandana Singh

Today, 8:40 PM

Japan’s health ministry panel authorized a plan to approve Novavax Inc’s (NASDAQ:NVAX) COVID-19 vaccine, which is set to be the fourth…

AZN

1 minute read

Phathom Pharma’s Vonoprazan Commercial Preparation Update At Needham Healthcare Conference

By Vandana Singh

Today, 8:40 PM

At the Needham Healthcare Conference, Phathom Pharmaceuticals Inc (NASDAQ:PHAT) says that licensor Takeda Pharmaceutical Co Ltd (NYSE: TAK) reported Takecab (vonoprazan) Q4 FY21…

PHAT

2 minute read

Takeda Reports TAKHZYRO Approved In Japan For Prophylaxis Against Acute attacks Of Hereditary Angioedema

By Benzinga Newsdesk

Today, 8:40 PM

− TAKHZYRO Approved for Adult and Pediatric Patients 12 Years of Age and Older1 − Approval Based on Results of Global Phase 3 HELP Study™, Phase 3 HELP OLE and a Phase 3 Study in Japanese Patients

TAK

1 minute read

Takeda’s Angioedema Drug Shows Promising Action Against COVID-19 Infection

By Vandana Singh

Today, 8:40 PM

Takeda Pharmaceutical Co Ltd’s (NYSE:TAK) Firazyr (icatibant), used to treat a blood vessel condition called angioedema, has shown promise…

TAK

1 minute read

Roche And AstraZeneca Settle Ultomiris Patent Lawsuit

By Vandana Singh

Today, 8:40 PM

Roche Holdings AG (OTC: RHHBY) has decided to close out a patent infringement lawsuit against AstraZeneca plc (NASDAQ: AZN), centering around the latter's newly acquired rare disease drug Ultomiris for a

AZN

1 minute read

Takeda Inks $2B Gene Therapy Pact With Code Biotherapeutics

By Vandana Singh

Today, 8:40 PM

Takeda Pharmaceutical Co Ltd (NYSE: TAK) has signed up for a gene therapy pact,

TAK

1 minute read

Real-World Analysis Show Takeda’s Alofisel Clinical Remission Rate At Six-Months

By Vandana Singh

Today, 8:40 PM

Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced the first six-month interim analysis results from INSPIRE study evaluating the Real-World Effectiveness and Safety of Alofisel (darvadstrocel).

TAK

1 minute read

FDA Approves Takeda’s Vonvendi As Prophylactic Treatment In Bleeding Disorder

By Vandana Singh

Today, 8:40 PM

The

TAK